MRKR:NASDAQMarker Therapeutics, Inc. Analysis

Marker Therapeutics trades at $1.66, comfortably above its 20‑day (≈$1.45) and 50‑day (≈$1.45) moving averages, while the 14‑day RSI sits at 61 and the MACD histogram remains in bullish territory, suggesting short‑term momentum is intact. Volume is on the rise and the stock respects a clear support zone near $1.17, with resistance around $1.79, framing a modest upside corridor. However, the company’s fundamentals are fragile: revenue has plunged 51%, gross and operating margins are negative, and operating cash flow is a sizable outflow exceeding $12 million, even though it holds roughly $16 million in cash. Volatility is elevated at nearly 80% over the past month and beta exceeds 1.2, underscoring heightened price swings and market sensitivity.
The latest quarter delivered an earnings surprise of +80% as loss per share narrowed to $0.04 versus expectations of a $0.21 loss, and Phase 1 “APOLLO” data revealed a 66% objective response rate (including 50% complete responses) in relapsed non‑Hodgkin lymphoma. These clinical signals, combined with a market‑derived upside potential of over 300% relative to current pricing, suggest the stock is priced well below its long‑term therapeutic upside despite near‑term cash‑burn concerns.